Influence of Technological Parameters on the Size of Benzocaine Particles in Ointments Formulated on Selected Bases

Compounding formulations, including semi-solid medication forms, must meet criteria related to specific stability and quality, during a period of their use. In suspension-type ointments, one the for assessment correct manufacturing is particle size, which in compounding preparation cannot exceed 90 µm. An appropriate level disintegration can be achieved via selection technological parameters qualitatively compatible excipients. this study, benzocaine ointments were prepared using levigation process. The time its application on size API suspension was evaluated. parallel, effect mixing co-solvent used precipitation active substance crystals emulsion storage these formulations 28 days investigated. Forty selected ointment bases: Pentravan®, Lekobaza, Lekobaza LUX, Eucerin Ointment I, Nourivan™ Antiox, Fitalite™, containing 2% benzocaine. Based results test, four study release kinetics vitro. These characterized by rate consistent with Higuchi model, fastest occurred from Eucerin-based ointment.